,12/8/2020,#,414.3,640.7,922.1,1,307.5,931.0,56.0,101.2,175.2,276.9,161.1,-4,0,%,0%,4,0,%,8,0,%,1,2,0%,0,4,0,0,8,0,0,1,2,00,1,6,00,2,0,18,20162017,营业收入（百万元）营业收入,YOY,20192020Q1-3,扣非归母净利润（百万元）扣非归母净利润,YOY,受疫情,影,响，,医,院 内镜诊,疗,量下,降，,公,司,营,收,和,扣,非,归,母净利,润,下滑。,22,.1,%,33,.0,%,41.8,%,44,.5,%,28,.2,%,24,.5,%,19,.5,%,17.7,%,19,.0,%,15,.3,%,13,.1,%,11,.5,%,5,.1,%,6,.9,%,9,.2,%,12.6,%,3.5%,10,.0,%,7,.4,%,6,.8,%,4,.7,%,6,.1,%,5,.7,%,5,.8,%,9,.0,%,4.7%,4.3%,3.3%,0%,2,0,%,4,0,%,6,0,%,8,0,%,1,0,0,%,2016,止血及闭合类,活检类,2017,扩张类,2018,E,M,R/ESD,类,2019,微波消融针,ER,CP,类,EUS/EBUS,类,肿瘤消融设备,其他,1,414.3640.7922.11,307.5931.056.,0,2,0,0,3,0,0,4,0,0,5,0,0,6,0,0,7,0,0,止血及闭合类,活检类,扩张类,EMR/ESD,类,ERCP,类,EUS/EBUS,类,2016 2017 2018,2019,100,0%,2,0,%,4,0,%,6,0,%,8,0,%,2,0,16,2,0,17,2,0,18,2,0,19,止血及闭合类,E,M,R/ESD,类,活检类,ER,CP,类,扩张类,EUS/EB,U,S,类,2,0200300400500600700止血及闭合类 活,52.3,63.8,68.6,88.91,3.0,2.5,2.3,6.36,0%,2,0,%,4,0,%,6,0,%,8,0,%,1,0,0,%,0,20,40,60,80,1,0,0,2,0,16,2017,微波消融针,微波消融针毛利率,2,0,18,2,0,19,微波消融设备,微波消融设备毛利率,3,52.363.868.688.913.02.52.36.36,17,.8,37,.9,49,.1,70,.4,0%,2%,4%,6%,8%,0,20,40,60,80,2,0,16,2017,研发投入（百万元）,20182019,研发投入占总营收的比重,%,327,.5,533,.9,79,.7,%,83,.,6%,85,.7,%,784.8,0%,3,0,%,6,0,%,9,0,%,0,3,0,0,6,0,0,9,0,0,2,0,16,2,0,18,2017,核心技术生产产品带来的收入（百万元）,核心技术生产产品带来的收入占总营收的比例,%,4,17.837.949.170.40%2%4%6%8%0204,5,5,58.6%,55.1%,54.9%,58.3%,40.6%,44.6%,44.4%,41.4%,0%,2,0,%,4,0,%,6,0,%,8,0,%,1,0,0%,2,0,16,2,0,19,20172018,中国大陆,国外,其他地区,39%,47%,39%,14%,22%,29%,60%,68%,75%,28%,32%,34%,43%,40%,32%,25%,61%,53%,33%,54%,44%,28%,0%,2,0,%,4,0,%,6,0,%,8,0,%,1,0,0,%,2,0,16,2,0,16,2,0,16,2,0,18,2,0,17,2,0,18,欧洲,2,0,17,2,0,18,美洲,2017,其他区域,经,销,直,销,贴 牌,6,58.6%55.1%54.9%58.3%40.6%44.6%,686,719,989,1227,1254,712,106,130,190,253,102,27,-8,0,%,-6,0,%,0%,2,0,%,4,0,%,6,0,%,0,2,0,0,8,0,0,1,0,00,1,2,00,1,4,00,2,0,15,2,0,18,2,0,19,2,0,Q,1,-3,20162017,营业收入（百万元）,营业收,入,YOY,归母净利润（百万元）,归母净利,润,YOY,269,352,407,229,175,232,61,73,55,233,255,3,6,11,19,(1,0,0),0,1,0,0,600,-2,0,%,200,180,1,161,97,179,400,-4,0,%,3,0,0,4,0,0,5,0,0,2,0,15,2,0,1,6,-4,2,0,17,2,0,1,8,-3,2,0,19,2,0,Q,1,-3,销售费用,管理费用研发费用,财务费用,7,686719989122712547121061301902,91%,89%,88%,82%,71%,68%,5%,7%,13%,23%,24%,6%,3%,6%,4%,5%,5%,7%,0%,2,0,%,4,0,%,6,0,%,8,0,%,1,0,0,%,2,0,15,2,0,H,1,2016,超声诊断设备,20172018,内窥镜配件及其他,2019,其他业务,44%,53%,59%,64%,63%,66%,0%,3,0,%,6,0,%,9,0,%,2,0,15,2,0,17,2,0,H,1,2016,超声诊断设备,2,0,18,内窥镜,2019,配件及其他,18%,19%,18%,19%,20%,8%,7%,8%,8%,10%,5%,0%,1,0,%,1,5,%,2,0,%,2,5,%,2,0,15,2,0,19,2016,研发投入比,20172018,申万医疗器械平均研发投入比,8,91%89%88%82%71%68%5%7%13%23%24,9,9,10,10,11,11,51,.1,81,.2,90,.3,122,.1,182.8,9,.2,22,.9,7,.3,37,.3,54,.7,-1,0,0%,0%,1,0,0,%,2,0,0%,3,0,0%,5,0,0,%,0,50,1,0,0,4,0,0,%,150,2,0,0,2,0,15,2,0,16,2,0,17,营业收入（百万元）营业收入,YOY,2,0,18,2,0,19,归母净利润（百万元）归母净利润,YOY,12,51.181.290.3122.1182.89.222.97,7.6%,8.5%,6.5%,6.3%,8.4%,8.5%,7.0%,9.1%,12.5%,5.7%,73.0%,9.2%,16.8%,64.7%,55.6%,0%,2,0,%,8,0,%,1,0,0%,止血闭合类,2017,E,M,R/ESD,类,2018,活检,类,E,RCP,类,诊疗仪器类,2019,其他业务,0%,2,0,%,60%,4,0,%,40%,6,0,%,8,0,%,2,0,19,2,0,17,止血闭合类,E,M,R/ES,D,类,2018,活检类,ER,CP,类,诊疗仪器类,0,20,40,60,80,1,0,0,1,2,0,止血闭合类,E,M,R/ESD,类,活检类,ERC,P,类,诊疗仪器类,2017 2018,2019,0,2,0,0000,4,0,0000,6,0,0000,8,0,0000,1,0,000,0,0,1,2,000,0,0,止血闭合类,E,M,R/ESD,类,活检类,ER,CP,类,诊疗仪器类,2,0,17,2018,2019,13,7.6%8.5%6.5%6.3%8.4%8.5%7.0%9.,6,.7,11.9,14,.9,0%,4%,8%,1,2,%,0,4,8,12,16,2,0,17,2,0,18,研发费用（百万元）,2019,研发费用占总营收的比例,%,85.0,115.5,172.2,9,0,%,9,1,%,9,2,%,9,3,%,9,4,%,9,5,%,0,50,1,0,0,1,5,0,2,0,0,2,0,17,2,0,19,2018,公司核心技术产品收入（百万元）,公司核心技术产品收入占主营业务收入比,例,%,14,6.711.914.90%4%8%12%0481216201,15,15,16,16,17,17,